HONG KONG, April 29, 2022 — Global Cord Blood Corporation (NYSE: CO, “GCBC” or the “Company”), China’s leading provider of cord blood collection, laboratory testing, hematopoietic stem cell processing and stem cell storage services, announced today that the Company will acquire 100% of Cellenkos, Inc (“CLNK”) and the rights to develop and commercialize all of its existing and future products worldwide except those related to CLNK’s existing collaboration with Incyte Corporation (Nasdaq: INCY, “Incyte”). [Read more…]
denovoMATRIX Launches Novel Microcarrier to Advance Cell and Gene Therapy Manufacturing
DRESDEN, Germany, May. 04, 2022 — denovoMATRIX GmbH, an innovator in cell and gene therapy (CGT) manufacturing, announced the launch of a novel microcarrier for increasing access to high-quality mesenchymal stromal cells (MSCs) for stem cell-based therapies. The product, termed beadMATRIX, is designed to enable MSC proliferation and harvest in xeno-/serum-free media with high efficiency and stemness.
Treefrog Therapeutics Expands Board with New Independent Members from the Cell Therapy Industy
• Melissa Carpenter, PhD, Chief Scientific Officer of US-based cell & gene therapy biotech ElevateBio’s Regenerative Medicine unit, joins as independent board member.
Avery Therapeutics, Inc Announces a Publication in Nature Scientific Reports Outlining Methods of Acquiring Cardiac MRI Endpoints in High Value Pre-Clinical Models of Heart Failure from University of Arizona Study
TUCSON, Ariz., – April 11, 2022 – Avery Therapeutics, Inc. (Avery), a privately held, pre-clinical stage therapeutics company, today announced a publication in the peer-reviewed scientific journal, Nature Scientific Reports, outlining a novel technique in cardiac magnetic resonance imaging (CMR) data acquisition utilizing smart-signal gradient recalled echo (GRE)-based array sequences, entitled, “Free-breathing gradient recalled echo-based CMR in a swine heart failure model,” (Morris, el al. (2022). Scientific Reports, 12(1). https://doi.org/10.1038/s41598-022-07611-8). [Read more…]
StemCyte Requests BLA from U.S. FDA for Allogeneic Cord Blood Product
StemCyte, a regenerative cell therapy company, has applied to the U.S. FDA for a BLA for its allogeneic umbilical cord hematopoietic progenitor cell product (HPC-Cord Blood)
StemCyte’s BLA has been accepted for quality review and StemCyte anticipates licensure in 2023
- « Previous Page
- 1
- …
- 34
- 35
- 36
- 37
- 38
- …
- 62
- Next Page »